Radiolabelled α-amylase inhibitors demonstrated 59.6% stomach retention, indicating potential for GIT-targeted imaging and antidiabetic treatment.
An 131 I-labeled α-amylase inhibitor shows exceptional stomach retention (59.6% ID per g) and sustained intestinal uptake, highlighting its promise as a GI-targeted antidiabetic agent and potential GI imaging probe.
No takes yet. Share an insight, caveat, or question.
Elsayed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: